World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
84
Citations
35923
World Ranking
14873
National Ranking
209

Juan José Lahuerta publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Juan José Lahuerta sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 457 publications — 50th percentile

50% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Juan José Lahuerta D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Juan José Lahuerta sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 84 D-Index — 27th percentile

27% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Juan José Lahuerta is affiliated with the Complutense University of Madrid in Spain. Their research primarily focuses on Medicine and Biochemistry, Genetics and Molecular Biology. The work spans several subfields including Hematology, Molecular Biology, Oncology, Genetics, and Immunology.

The scientist's main research topics include Multiple Myeloma Research and Treatments, Protein Degradation and Inhibitors, Peptidase Inhibition and Analysis, Amyloidosis: Diagnosis, Treatment, Outcomes, Cancer Treatment and Pharmacology, Myeloproliferative Neoplasms: Diagnosis and Treatment, and Chronic Lymphocytic Leukemia Research.

Juan José Lahuerta has contributed substantially to scholarly literature. Selected recent papers include:

  • Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma: A European Myeloma Network (EMN) Report Within the HARMONY Project, 2022, Journal of Clinical Oncology
  • Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial, 2021, The Lancet Oncology
  • Immunogenomic identification and characterization of granulocytic myeloid-derived suppressor cells in multiple myeloma, 2020, Blood
  • Deep MRD profiling defines outcome and unveils different modes of treatment resistance in standard- and high-risk myeloma, 2020, Blood
  • Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma, 2020, Blood Cancer Journal

The frequent collaborators of Juan José Lahuerta include Jesús F. San Miguel, María-Victoria Mateos, Joaquin Martínez-López, Albert Oriol, and Noemí Puig.

Regarding publication venues, contributions have appeared most often in:

  • Blood
  • Clinical Lymphoma Myeloma & Leukemia
  • Journal of Clinical Oncology
  • Blood Cancer Journal
  • Blood Advances

Best Publications

  • International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma.

    S. Vincent Rajkumar;Meletios A. Dimopoulos;Antonio Palumbo;Joan Blade

  • International staging system for multiple myeloma.

    Philip R. Greipp;Jesus San Miguel;Brian G.M. Durie;John J. Crowley

  • Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group

    Antonio Palumbo;Hervé Avet-Loiseau;Stefania Oliva;Henk M. Lokhorst

  • Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study

    S. K. Kumar;J. H. Lee;J. J. Lahuerta;G. Morgan

  • Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma

    J Flores-Montero;L Sanoja-Flores;B Paiva;N Puig

  • Lenalidomide plus Dexamethasone for High-Risk Smoldering Multiple Myeloma

    María-Victoria Mateos;Miguel-Teodoro Hernández;Pilar Giraldo;Javier de la Rubia

  • Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial

    María-Victoria Mateos;Albert Oriol;Joaquín Martínez-López;Norma Gutiérrez

  • Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study.

    Laura Rosiñol;Albert Oriol;Ana Isabel Teruel;Dolores Hernández

  • Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study

    María-Victoria Mateos;María-Victoria Mateos;José-M. Hernández;José-M. Hernández;Miguel-T. Hernández;Miguel-T. Hernández;Norma-C. Gutiérrez;Norma-C. Gutiérrez

  • Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation.

    Bruno Paiva;Maria-Belén Vidriales;Jorge Cerveró;Gema Mateo

  • Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma

    Joaquin Martinez-Lopez;Juan J. Lahuerta;François Pepin;Marcos González

  • Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group

    C. Fernández De Larrea;R. A. Kyle;B. G.M. Durie;H. Ludwig

  • Role of Magnetic Resonance Imaging in the Management of Patients With Multiple Myeloma: A Consensus Statement

    Meletios A. Dimopoulos;Jens Hillengass;Saad Usmani;Elena Zamagni

  • Influence of Pre- and Post-Transplantation Responses on Outcome of Patients With Multiple Myeloma: Sequential Improvement of Response and Achievement of Complete Response Are Associated With Longer Survival

    Juan José Lahuerta;Maria Victoria Mateos;Joaquin Martínez-López;Laura Rosiñol

  • High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma

    Bruno Paiva;Norma C. Gutiérrez;Laura Rosiñol;María-Belén Vídriales

  • International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders

    Jens Hillengass;Saad Usmani;S Vincent Rajkumar;Brian G M Durie

  • A prospective PETHEMA study of tandem autologous transplantation versus autograft followed by reduced-intensity conditioning allogeneic transplantation in newly diagnosed multiple myeloma.

    Laura Rosiñol;José Antonio Pérez-Simón;Anna Sureda;Javier de la Rubia

  • Autologous Stem-Cell Transplantation for Hodgkin’s Disease: Results and Prognostic Factors in 494 Patients From the Grupo Español de Linfomas/Transplante Autólogo de Médula Ósea Spanish Cooperative Group

    A Sureda;R Arranz;A Iriondo;E Carreras

  • Maintenance therapy with bortezomib plus thalidomide or bortezomib plus prednisone in elderly multiple myeloma patients included in the GEM2005MAS65 trial

    María-Victoria Mateos;Albert Oriol;Joaquín Martínez-López;Norma Gutiérrez

  • Erratum: Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study (Leukemia (2012) 26 (149-157) DOI: 10.1038/leu.2011.196)

    S. K. Kumar;J. H. Lee;J. J. Lahuerta;G. Morgan

Frequent Co-Authors

Maria-Victoria Mateos
Maria-Victoria Mateos University of Salamanca
Joan Bladé
Joan Bladé University of Barcelona
Albert Oriol
Albert Oriol Autonomous University of Barcelona
Jesús F. San Miguel
Jesús F. San Miguel University of Navarra
Ramón García-Sanz
Ramón García-Sanz University of Salamanca
Anna Sureda
Anna Sureda Autonomous University of Barcelona
Alberto Orfao
Alberto Orfao University of Salamanca
Felipe Prosper
Felipe Prosper University of Navarra
Michele Cavo
Michele Cavo University of Bologna
María José Calasanz
María José Calasanz University of Navarra

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring medical careers in the USA extends beyond traditional MD programs. Many students consider alternative or complementary online degrees that offer flexible learning and diverse pathways into healthcare.

For those interested in healthcare leadership, enrolling in one of the cheapest mha online programs can be a cost-effective route to management roles in hospitals and clinics. Nurses aiming to advance their practice can explore cheapest bsn to dnp programs, designed for working RNs who wish to achieve a terminal degree in nursing.

If pharmacy is your focus, consider accredited online pharm d programs to gain the qualifications needed for advanced roles in pharmaceuticals, research, and patient care. Additionally, those looking for entry-level positions in the rapidly growing field of health data may start with a reputable him associate degree online.

These flexible, affordable online options provide valuable alternatives to traditional medical degrees and open up varied career opportunities in healthcare.

Best Scientists Citing Juan José Lahuerta

Trending Scientists

Recently Published Articles